Yuan Min Wang1, Karli Shaw1, Geoff Yu Zhang1, Edmund Y M Chung1, Min Hu2, Qi Cao2, Yiping Wang2, Guoping Zheng2, Huiling Wu3,4, Steven J Chadban3,4, Hugh J McCarthy1, David C H Harris2, Fabienne Mackay5, Shane T Grey6, Stephen I Alexander7. 1. Centre for Kidney Research, The Children's Hospital at Westmead, The University of Sydney, Westmead, New South Wales, Australia. 2. Centre for Transplantation and Renal Research, University of Sydney at Westmead Millennium Institute, Westmead, New South Wales, Australia. 3. Kidney Node Laboratory, The Charles Perkins Centre, University of Sydney, Camperdown, New South Wales, Australia. 4. Department of Renal Medicine, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia. 5. QIMR, University of Queensland, Brisbane, Queensland, Australia. 6. Transplantation Immunology Group, Garvan Institute of Medical Research, Sydney, Australia. 7. Centre for Kidney Research, The Children's Hospital at Westmead, The University of Sydney, Westmead, New South Wales, Australia stephen.alexander@health.nsw.gov.au.
Abstract
BACKGROUND: The cytokine IL-33 is an activator of innate lymphoid cells 2 (ILC2s) in innate immunity and allergic inflammation. B cell activating factor (BAFF) plays a central role in B cell proliferation and differentiation, and high levels of this protein cause excess antibody production, including IgA. BAFF-transgenic mice overexpress BAFF and spontaneously develop glomerulonephritis that resembles human IgA nephropathy. METHODS: We administered IL-33 or PBS to wild-type and BAFF-transgenic mice. After treating Rag1-deficient mice with IL-33, with or without anti-CD90.2 to preferentially deplete ILC2s, we isolated splenocytes, which were adoptively transferred into BAFF-transgenic mice. RESULTS: BAFF-transgenic mice treated with IL-33 developed more severe kidney dysfunction and proteinuria, glomerular sclerosis, tubulointerstitial damage, and glomerular deposition of IgA and C3. Compared with wild-type mice, BAFF-transgenic mice exhibited increases of CD19+ B cells in spleen and kidney and ILC2s in kidney and intestine, which were further increased by administration of IL-33. Administering IL-33 to wild-type mice had no effect on kidney function or histology, nor did it alter the number of ILC2s in spleen, kidney, or intestine. To understand the role of ILC2s, splenocytes were transferred from IL-33-treated Rag1-deficient mice into BAFF-transgenic mice. Glomerulonephritis and IgA deposition were exacerbated by transfer of IL-33-stimulated Rag1-deficient splenocytes, but not by ILC2 (anti-CD90.2)-depleted splenocytes. Wild-type mice infused with IL-33-treated Rag1-deficient splenocytes showed no change in kidney function or ILC2 numbers or distribution. CONCLUSIONS: IL-33-expanded ILC2s exacerbated IgA glomerulonephritis in a mouse model. These findings indicate that IL-33 and ILC2s warrant evaluation as possible mediators of human IgA nephropathy.
BACKGROUND: The cytokine IL-33 is an activator of innate lymphoid cells 2 (ILC2s) in innate immunity and allergic inflammation. B cell activating factor (BAFF) plays a central role in B cell proliferation and differentiation, and high levels of this protein cause excess antibody production, including IgA. BAFF-transgenic mice overexpress BAFF and spontaneously develop glomerulonephritis that resembles human IgA nephropathy. METHODS: We administered IL-33 or PBS to wild-type and BAFF-transgenic mice. After treating Rag1-deficient mice with IL-33, with or without anti-CD90.2 to preferentially deplete ILC2s, we isolated splenocytes, which were adoptively transferred into BAFF-transgenic mice. RESULTS: BAFF-transgenic mice treated with IL-33 developed more severe kidney dysfunction and proteinuria, glomerular sclerosis, tubulointerstitial damage, and glomerular deposition of IgA and C3. Compared with wild-type mice, BAFF-transgenic mice exhibited increases of CD19+ B cells in spleen and kidney and ILC2s in kidney and intestine, which were further increased by administration of IL-33. Administering IL-33 to wild-type mice had no effect on kidney function or histology, nor did it alter the number of ILC2s in spleen, kidney, or intestine. To understand the role of ILC2s, splenocytes were transferred from IL-33-treated Rag1-deficient mice into BAFF-transgenic mice. Glomerulonephritis and IgA deposition were exacerbated by transfer of IL-33-stimulated Rag1-deficient splenocytes, but not by ILC2 (anti-CD90.2)-depleted splenocytes. Wild-type mice infused with IL-33-treated Rag1-deficient splenocytes showed no change in kidney function or ILC2 numbers or distribution. CONCLUSIONS: IL-33-expanded ILC2s exacerbated IgA glomerulonephritis in a mouse model. These findings indicate that IL-33 and ILC2s warrant evaluation as possible mediators of human IgA nephropathy.
Authors: Douglas D McCarthy; Julie Kujawa; Cheryl Wilson; Adrian Papandile; Urjana Poreci; Elisa A Porfilio; Lesley Ward; Melissa A E Lawson; Andrew J Macpherson; Kathy D McCoy; York Pei; Lea Novak; Jeannette Y Lee; Bruce A Julian; Jan Novak; Ann Ranger; Jennifer L Gommerman; Jeffrey L Browning Journal: J Clin Invest Date: 2011-09-01 Impact factor: 14.808
Authors: Qi Cao; Yiping Wang; Zhiguo Niu; Chengshi Wang; Ruifeng Wang; Zhiqiang Zhang; Titi Chen; Xin Maggie Wang; Qing Li; Vincent W S Lee; Qingsong Huang; Jing Tan; Minghao Guo; Yuan Min Wang; Guoping Zheng; Di Yu; Stephen I Alexander; Hui Wang; David C H Harris Journal: J Am Soc Nephrol Date: 2018-01-02 Impact factor: 10.121
Authors: Bengt C Fellström; Jonathan Barratt; Heather Cook; Rosanna Coppo; John Feehally; Johan W de Fijter; Jürgen Floege; Gerd Hetzel; Alan G Jardine; Francesco Locatelli; Bart D Maes; Alex Mercer; Fernanda Ortiz; Manuel Praga; Søren S Sørensen; Vladimir Tesar; Lucia Del Vecchio Journal: Lancet Date: 2017-03-28 Impact factor: 79.321
Authors: Rosanna Coppo; Stéphan Troyanov; Roberta Camilla; Ronald J Hogg; Daniel C Cattran; H Terence Cook; John Feehally; Ian S D Roberts; Alessandro Amore; Charles E Alpers; Jonathan Barratt; Francois Berthoux; Stephen Bonsib; Jan A Bruijn; Vivette D'Agati; Giuseppe D'Amico; Steven N Emancipator; Francesco Emma; Franco Ferrario; Fernando C Fervenza; Sandrine Florquin; Agnes B Fogo; Colin C Geddes; Hermann J Groene; Mark Haas; Andrew M Herzenberg; Prue A Hill; Stephen I Hsu; J Charles Jennette; Kensuke Joh; Bruce A Julian; Tetsuya Kawamura; Fernand M Lai; Lei S Li; Philip K Li; Zhi H Liu; Sergio Mezzano; F Paolo Schena; Yasuhiko Tomino; Patrick D Walker; Haiyan Wang; Jan J Weening; Norishige Yoshikawa; Hong Zhang Journal: Kidney Int Date: 2010-03-03 Impact factor: 10.612
Authors: Richard Furie; Brad H Rovin; Frédéric Houssiau; Ana Malvar; Y K Onno Teng; Gabriel Contreras; Zahir Amoura; Xueqing Yu; Chi-Chiu Mok; Mittermayer B Santiago; Amit Saxena; Yulia Green; Beulah Ji; Christi Kleoudis; Susan W Burriss; Carly Barnett; David A Roth Journal: N Engl J Med Date: 2020-09-17 Impact factor: 91.245